18 active shortage notices across 9 countries.
Last updated 2 Aug 2026 · sourced from official medicines regulators
| Australia | high | 2 | 31 Dec 2024 | — | TGA |
| Colombia | high | 1 | 10 Nov 2025 | — | INVIMA |
| Belgium | medium | 2 | 20 Feb 2026 | 30 Jun 2026 | FAMHP |
| Greece | medium | 2 | 9 Apr 2025 | — | EOF |
| Peru | medium | 1 | 1 Feb 2024 | 3 Dec 2025 | DIGEMID |
| Spain | medium | 1 | 31 Jan 2024 | 29 Aug 2026 | AEMPS |
| Malaysia | medium | 1 | 1 Jan 2021 | — | NPRA |
Yes. As of the latest regulator updates, Bortezomib has 18 active shortage notices across 9 countries (Italy, Canada, Australia, Colombia, Belgium, Greece and more). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Bortezomib shortages to product discontinuation, supply-chain disruption, unexpected increases in demand. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 3 Dec 2025 to 29 Aug 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Amsacrine · Eribulin Mesylate · Carboplatino · Cisplatino · Oxaliplatino · Cisplatin
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.